Stocks · News reference
VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA))), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 11:09 AM
- Checked
- Jul 20, 2026, 11:09 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Veraxa Biotech Files Prospectus Related To The Resale Of Up To 25M Ordinary Shares By The Selling Shareholder
-SEC FIling
Read original at benzingaVeraxa Biotech shares are trading higher after the company announced the advancement of the bispecific ADC program VXA-222.
Read original at benzingaVERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
Read original at benzinga